You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies plan to combine blockchain technology, artificial intelligence, and genomics for medical analytics.
Telehealth service provider GeneMatters is teaming with Clear Genetics to extend the reach of its genetic counselors for health systems and labs.
With the help of AI, blockchain, and a new cryptocurrency, Nebula wants to give patients more control of their genomic data.
The company is developing a platform for synthesizing biomedical knowledge from scientific, regulatory, and commercial literature.
The companies will pair Freenome's AI genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.
The partners will develop and implement bioinformatics tools, pipelines, and techniques to improve molecular profiling for research and clinical oncology.
George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.